The purpose of this Funding Opportunity Announcement (FOA) is to support translational and clinical research that promotes therapeutic development for primary glomerular diseases. The emphasis of this FOA is specifically on chronic forms of minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), immunoglobulin A nephropathy (IGAN), and idiopathic membranous nephropathy (IMN).
As the School of Medicine may only submit 1 proposal for this opportunity, the Office of Research and Graduate Education has established an internal review process to determine which proposal(s) will move forward to the funding agency.
To apply for this funding opportunity, please email a 1-2 page letter of intent describing your proposed aims and approach, a list of all anticipated investigators, and a biosketch of the PI to RGE at rgeopps@uw.edu by Thursday, December 20, 2012. Applicants will be notified as soon as a decision is reached.
Investigators who identify a grant, award or fellowship program that restricts the number of applications that can be submitted from an Institution should immediately contact their Chairperson, Associate Dean for Research (or Dean, if no ADR) and the Office of Research (see below) if they intend to prepare a response. Failure to do so, or to meet the deadlines for submission of pre-proposal, will preclude submission of the application through the Office of Sponsored Programs.
For general inquiries, or to request a listing of a limited submission opportunity that should be but is not already listed, please email us at research@uw.edu.